The Industry, Trade and Labor Ministry announced on Wednesday that the pharmaceutical company Scigen, headquartered in Singapore, intends over the next year to expand its research and development projects in Israel.
Scigen manufactures the Hepatitis B vaccine, the main component for which was developed in Israel by Biotechnology General, said Rachel Roei, director of the Ministry's investment promotion center. Scigen, founded in 1988, is one of Singapore's leading bio-pharmaceutical companies and is traded on the Australian Stock Exchange.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>